Drug Profile
Research programme: antibacterials - Spero Therapeutics/Roche
Alternative Names: Multiple virulence factor Regulator inhibitors - Spero; MvfR inhibitors - Spero; MvfR programme - SperoLatest Information Update: 25 Sep 2019
Price :
$50
*
At a glance
- Originator Spero Therapeutics
- Class Antibacterials; Small molecules
- Mechanism of Action Transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Gram-negative infections; Pseudomonal infections
Most Recent Events
- 28 Sep 2018 No recent reports of development identified for preclinical development in Pseudomonal-infections in USA
- 28 May 2018 No recent reports of development identified for preclinical development in Gram-negative-infections(Treatment-resistant) in USA
- 25 Apr 2017 Pharmacodynamic results from a preclinical study in Pseudomonal infections presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2017)